Absence of Relationship Between Steroid Hormone Levels and Prostate Cancer Tumor Grade

Urology

Volumn 73, Issue 2, 2009, Pages 356-361

  Sher, David J ^a   Mantzoros, Christos ^b   Jacobus, Susanna ^c   Regan, Meredith M ^c   Lee, Gwo Shu ^c   Oh, William K ^c  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; STEROID HORMONE; TESTOSTERONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; GLEASON SCORE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL;

AGED; BIOPSY; ESTRADIOL; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 58649101843     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.07.068     Document Type: Article

References (16)

1. Huggins C., Stevens Jr. R.E., and Hodges C.V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
2. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
3. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
4. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
5. Schatzl G., Madersbacher S., Thurridl T., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 (2001) 52-58
6. Hoffman M.A., DeWolf W.C., and Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824-827
7. Fodstad P., Bjoro T., Torlakovic G., et al. No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer. J Urol 168 (2002) 1188-1192
8. Platz E.A., Leitzmann M.F., Rifai N., et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14 (2005) 1262-1269
9. Oh W.K., Hayes J., Evan C., et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 5 (2006) 61-66
10. Amling C.L., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22 (2004) 439-445
11. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
12. Brawley O.W., Ford L.G., Thompson I., et al. 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 3 (1994) 177-182
13. Nishiyama T., Ikarashi T., Hashimoto Y., et al. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 176 (2006) 1387-1391
14. Travis R.C., Key T.J., Allen N.E., et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121 (2007) 1331-1338
15. Chen C., Weiss N.S., Stanczyk F.Z., et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 12 (2003) 1410-1416
16. Crawford E.D., Barqawi A.B., O'Donnell C., et al. The association of time of day and serum testosterone concentration in a large screening population. BJU Int 100 (2007) 509-513